Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07003984 · ClinicalTrials.gov registry record · Phase 3
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
A Phase 3 study of Chikungunya Virus, sponsored by Bavarian Nordic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
- 9
- Study locations
NCT07003984 is a Phase 3 study of Chikungunya Virus that is actively recruiting participants, run by Bavarian Nordic. The registered enrollment target is 720 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT07003984, a Phase 3 study of Chikungunya Virus, is actively recruiting participants, sponsored by Bavarian Nordic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to \<12 years of age.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CHIKV VLP vaccine
Study Locations (9)
Florida
- Acevedo Clinical Research - Miami
- Hope Research Network - Miami
California
- ARK Clinical Research, LLC - Fountain Valley
District of Columbia
- Emerson Clinical Research Institute- DC - Washington D.C.
Nebraska
- Velocity Clinical Research-Omaha - Omaha
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Texas
- KidCare Pediatrics - Beaumont
Utah
- Velocity Clinical Research - Salt Lake City - West Jordan
Puerto Rico
- Caribbean Medicine Center - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07003984
The ClinicalTrials.gov registry entry for NCT07003984 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chikungunya Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07003984 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT07003984 about?
NCT07003984 is a clinical study titled "A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.". The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to \<12 years of age.
What is the current status of trial NCT07003984?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2025-06-05. Estimated completion is 2028-12.
What conditions does trial NCT07003984 study?
This clinical trial studies the following conditions: Chikungunya Virus.
What interventions are being tested in trial NCT07003984?
The interventions under investigation include: Placebo (BIOLOGICAL), CHIKV VLP vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07003984?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07003984 being conducted?
This trial has 9 study locations across California, District of Columbia, Florida, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.